Literature DB >> 35460723

Prevalence of Americans reporting a family history of cancer indicative of increased cancer risk: Estimates from the 2015 National Health Interview Survey.

Marie T Kumerow1, Juan L Rodriguez2, Shifan Dai3, Katherine Kolor4, Melissa Rotunno5, Lucy A Peipins6.   

Abstract

The collection and evaluation of family health history in a clinical setting presents an opportunity to discuss cancer risk, tailor cancer screening recommendations, and identify people with an increased risk of carrying a pathogenic variant who may benefit from referral to genetic counseling and testing. National recommendations for breast and colorectal cancer screening indicate that men and women who have a first-degree relative affected with these types of cancers may benefit from talking to a healthcare provider about starting screening at an earlier age and other options for cancer prevention. The prevalence of reporting a first-degree relative who had cancer was assessed among adult respondents of the 2015 National Health Interview Survey who had never had cancer themselves (n = 27,999). We found 35.6% of adults reported having at least one first-degree relative with cancer at any site. Significant differences in reporting a family history of cancer were observed by sex, age, race/ethnicity, educational attainment, and census region. Nearly 5% of women under age 50 and 2.5% of adults under age 50 had at least one first-degree relative with breast cancer or colorectal cancer, respectively. We estimated that 5.8% of women had a family history of breast or ovarian cancer that may indicate increased genetic risk. A third of U.S. adults who have never had cancer report a family history of cancer in a first-degree relative. This finding underscores the importance of using family history to inform discussions about cancer risk and screening options between healthcare providers and their patients. Published by Elsevier Inc.

Entities:  

Keywords:  Family history; Hereditary breast and ovarian cancer syndrome; Hereditary neoplastic syndromes; Neoplasm; Public health surveillance

Mesh:

Year:  2022        PMID: 35460723      PMCID: PMC9162122          DOI: 10.1016/j.ypmed.2022.107062

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.637


  52 in total

1.  Clinically relevant changes in family history of cancer over time.

Authors:  Argyrios Ziogas; Nora K Horick; Anita Y Kinney; Jan T Lowery; Susan M Domchek; Claudine Isaacs; Constance A Griffin; Patricia G Moorman; Karen L Edwards; Deirdre A Hill; Jonathan S Berg; Gail E Tomlinson; Hoda Anton-Culver; Louise C Strong; Carol H Kasten; Dianne M Finkelstein; Sharon E Plon
Journal:  JAMA       Date:  2011-07-13       Impact factor: 56.272

2.  Validation of family cancer history data in high-risk families: the influence of cancer site, ethnicity, kinship degree, and multiple family reporters.

Authors:  Parisa Tehranifar; Hui-Chen Wu; Tom Shriver; Ann J Cloud; Mary Beth Terry
Journal:  Am J Epidemiol       Date:  2015-01-07       Impact factor: 4.897

3.  CDC Grand Rounds: Family History and Genomics as Tools for Cancer Prevention and Control.

Authors:  Juan L Rodriguez; Cheryll C Thomas; Greta M Massetti; Debra Duquette; Lindsay Avner; John Iskander; Muin J Khoury; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-11-25       Impact factor: 17.586

4.  Predictors of Self-Reported Family Health History of Breast Cancer.

Authors:  Luisel J Ricks-Santi; Nicole Thompson; Altovise Ewing; Barbara Harrison; Kimberly Higginbotham; Cherie Spencer; Adeyinka Laiyemo; Robert DeWitty; Lori Wilson; Sara Horton; Jacqueline Dunmore-Griffith; Carla Williams; Wayne Frederick
Journal:  J Immigr Minor Health       Date:  2016-10

5.  Interviews with primary care physicians regarding taking and interpreting the cancer family history.

Authors:  Marie E Wood; Alan Stockdale; Brian S Flynn
Journal:  Fam Pract       Date:  2008-09-01       Impact factor: 2.267

6.  Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.

Authors:  Marie E Wood; Pamela Kadlubek; Trang H Pham; Dana S Wollins; Karen H Lu; Jeffrey N Weitzel; Michael N Neuss; Kevin S Hughes
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

7.  Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention.

Authors:  Scott D Ramsey; Paula Yoon; Ramal Moonesinghe; Muin J Khoury
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

Review 8.  Initiatives to Scale Up and Expand Reach of Cancer Genomic Services Outside of Specialty Clinical Settings: A Systematic Review.

Authors:  Yue Guan; Colleen M McBride; Hannah Rogers; Jingsong Zhao; Caitlin G Allen; Cam Escoffery
Journal:  Am J Prev Med       Date:  2020-11-07       Impact factor: 5.043

9.  Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.

Authors:  Eloise Chapman-Davis; Zhen Ni Zhou; Jessica C Fields; Melissa K Frey; Bailey Jordan; Katherine J Sapra; Sudeshna Chatterjee-Paer; Ann D Carlson; Kevin M Holcomb
Journal:  J Gen Intern Med       Date:  2020-07-27       Impact factor: 5.128

10.  Contribution of extended family history in assessment of risk for breast and colon cancer.

Authors:  Benjamin L Solomon; Todd Whitman; Marie E Wood
Journal:  BMC Fam Pract       Date:  2016-09-01       Impact factor: 2.497

View more
  1 in total

1.  BTN3A3 inhibits the proliferation, migration and invasion of ovarian cancer cells by regulating ERK1/2 phosphorylation.

Authors:  Sihan Chen; Zhangyun Li; Yanyan Wang; Shaohua Fan
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.